Semaglutide on Long-Term Outcomes in Heart Failure Patients with co-existing chronic kidney disease: A US Cohort Propensity-Matched Study Saturday, May 3, 2025
There is no significant interaction with renal function, and the benefits of GLP-1 RAs remain consistent irrespective of the timing of patient inclusion in the trials
And drugs whose approval is expedited by the FDA are more likely to have black box warnings added after theyve already been prescribed to patients
GLP-1 Benefit Analysis Early evidence shows that GLP1s reduce certain medical expensesparticularly hospitalizations tied to diabetes complications and other chronic conditions that are more prevalent with obesity
Jasien JV, Laurie SS, Lee SMC, Martin DS, Kemp DT, Ebert DJ, et al
The visit fee includes a prescription valid for up to a year (depending on the condition) and on-going support from the healthcare practitioner or pharmacist